HOME >> BIOLOGY >> NEWS
Novel, even unlikely drugs may curb childhood leukemia

Philadelphia, Pa.While survival rates for childhood leukemias have soared in the past 30 years, about a quarter of pediatric cases remain stubbornly resistant to treatment. As a new attack strategy, scientists are adapting recent discoveries about cell development to coax leukemia cells back to normal growth patterns or to reprogram them into committing suicide.

"Reaching the next level of leukemia treatment will require many new approaches that draw upon our expanding knowledge about how healthy cells differentiate during normal growth and development," said Beverly Lange, M.D., director of experimental therapeutics within the Division of Oncology at The Childrens Hospital of Philadelphia, who is an expert in these new attack strategies.

Unlike conventional cancer drugs, the newer drugs are based on detailed knowledge of cellular mechanisms that can be used to manipulate cancer cells in a way that is gentler to surrounding healthy cells.

Oncologists at Childrens Hospital are investigating a number of novel, even unlikely, drugs as highly specific, less toxic weapons against childhood leukemia. For example:
-- A form of vitamin A is being used to reprogram a cancer cell into becoming a harmless, normal white blood cell.
-- Borrowing from its use in traditional Chinese medicine, carefully controlled doses of arsenic can trigger cancer cells to commit suicide by mimicking the normal developmental process of "apoptosis," or programmed cell death.
-- A new type of leukemia drug, the bioengineered compound Glivec, can block the genetic signals that direct cancer cells to grow, while leaving normal cells largely unharmed.
-- The naturally occurring protein interleukin-2 may kick-start the bodys immune system to better fight leukemia.

Taming cancer cells

Some experimental new treatments rely on methods that neutralize or disrupt cancer cells rather than killing them outright in a frontal attack. "Most conventional ca
'"/>

Contact: John Ascenzi
ascenzi@email.chop.edu
215-590-7332
Children's Hospital of Philadelphia
14-May-2001


Page: 1 2 3 4

Related biology news :

1. Goals unlikely to protect Gulf of Mexico shrimp industry
2. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
3. Sex selection for social reasons unlikely to skew gender balance in Germany and UK
4. An unlikely new weapon against a deadly bacteria in oysters: A virus
5. Suppressing entire immune system unlikely to be best way to treat autoimmune diseases, new findings show
6. Depressed heart attack survivors unlikely to change behavior
7. New model of staph drug resistance implicates unlikely protein
8. One in three physicians unlikely to get routine medical care
9. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
10. New and better drugs for tuberculosis goal of UH professor
11. New technique helps scientists reveal interactions between genes and drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/9/2019)... ... July 08, 2019 , ... ... of Danisco’s ownership of the innovation behind two Danisco amylase patent applications (EP2859097 ... could be based on prior art was without merit and awarded costs to ...
(Date:6/24/2019)... ... 24, 2019 , ... According to the World Health Organization , over ... STDs: chlamydia, gonorrhea, trichomoniasis (or "trich") and syphilis. And that’s not counting HIV. ... men accounted for the largest number of HIV diagnoses (9,807), followed by Hispanic/Latino men ...
(Date:6/16/2019)... (PRWEB) , ... June 14, 2019 , ... ... Americans invited to lecture at the fifth annual Neodent World Congress. Attended by ... the innovative progress and latest advancements in the world of dentistry. The three-day ...
Breaking Biology News(10 mins):
(Date:7/11/2019)... ... ... At the most recent stem cell training course in Las Vegas ... Heroes Program. The Veterans included individuals and families from all over the US, with ... military Veteran, teacher or first responder to receive a regenerative therapy at a training ...
(Date:6/18/2019)... ... June 17, 2019 , ... ... entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) ... rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 ...
(Date:6/11/2019)... CITY, Calif. (PRWEB) , ... June 10, 2019 ... ... (IOPP) today announced IOPP will add 80 of its scientific journals to DeepDyve’s ... of physics-related content to DeepDyve’s continually expanding library of more than 20 million ...
(Date:5/31/2019)... TORONTO (PRWEB) , ... May 29, 2019 , ... For ... but the toughest forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led ... a patient’s own T cells with engineered T cell receptors known as “CARs”. The ...
Breaking Biology Technology:
Cached News: